Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
October 2021
-
Key ReleaseNovartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancerAd hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS)…
-
Media ReleaseNovartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccineAt least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia New…
-
Media ReleaseGlobal Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killerInvisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (…
-
Media ReleaseKesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosisALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there…
-
Media ReleaseNovartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edemaRegulatory decisions for Beovu (brolucizumab) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed…
-
Media ReleaseSandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibioticsSandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading…
-
Media ReleaseNovartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosisNovartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)Novartis will be commencing Phase III…
-
Media ReleaseSandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic DrugsCompany previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz,…
September 2021
-
Media ReleaseNovartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticariaResults from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile…
-
Media ReleaseNovartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissionsReached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and…
-
Media ReleaseNovartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malariaNovartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malariaIn the Phase 2b study conducted in children…
-
Media ReleaseNew data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasisNew findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1 Patient satisfaction with 300 mg autoinjector…
Pagination
- ‹ Previous page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- …
- 88
- › Next page